Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) – Drugs In Development, 2021, provides an overview of the Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline landscape.Ebola is a rare but deadly viral infection that causes bleeding inside and outside the body. Signs and symptoms include fever, severe headache, joint and muscle aches, sore throat, nausea and vomiting, diarrhea, chest pain and cough. Supportive therapy includes oxygen therapy, blood transfusions, intravenous fluids and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Ebolavirus Infections (Ebola Hemorrhagic Fever) and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 1, 8, 61, 26 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 4, 13 and 8 molecules, respectively.Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease).- The pipeline guide reviews pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. – The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.- The pipeline guide reviews key companies involved in Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all their major and minor projects.- The pipeline guide evaluates Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. – The pipeline guide reviews latest news related to pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.- Find and recognize significant and varied types of therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease).- Classify potential new clients or partners in the target demographic.- Develop tactical initiatives by understanding the focus areas of leading companies.- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.- Formulate corrective measures for pipeline projects by understanding Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline depth and focus of Indication therapeutics.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Abivax SA

AIkido Pharma Inc

Akshaya Bio Inc

AlphaVax Inc

AnGes Inc

ANP Technologies Inc

AntoXa Corp

Arisan Therapeutics Inc

Auro Vaccines LLC

Avipero Ltd

Beijing Combio Pharmaceuticals Ltd

Beijing Mabworks Biotech Co Ltd

Bharat Biotech Ltd

BioComo Inc

BioCryst Pharmaceuticals Inc

BioFactura Inc

Biotron Ltd

Celdara Medical LLC

Chicago Biosolutions Inc

Cocrystal Pharma Inc

Collaborations Pharmaceuticals Inc

Eisai Co Ltd

Emergent BioSolutions Inc

Emergex Vaccines Holding Ltd

Etubics Corp

Fab’entech SA

Fibroplate Inc

Flow Pharma Inc

Fox Chase Chemical Diversity Center Inc

Galactica Biotech Ltd

Gamaleya Federal Research Center of Epidemiology and Microbiology

GeoVax Labs Inc

Gilead Sciences Inc

Global BioLife Inc Ltd

Greffex Inc

H&P Labs Inc

IDBiologics Inc

Inovio Pharmaceuticals Inc

Integral Molecular Inc

Integrated BioTherapeutics Inc

IntelliStem Technologies Inc

Johnson & Johnson

Mapp Biopharmaceutical Inc

Merck & Co Inc

Microbiotix Inc

Micropharm Ltd

Novavax Inc

Oita University Institute of Advanced Medicine Inc

OncXerna Therapeutics Inc

Orgenesis Inc

Ostrich Pharma USA Inc

Palisades Therapeutics

PanThera Biopharma LLC

Phelix Therapeutics LLC

Phoenix Biotechnology Inc

Public Health Vaccines LLC

Regeneron Pharmaceuticals Inc

Riboscience LLC

Rodos BioTarget GmbH

SAB Biotherapeutics Inc

Secarna Pharmaceuticals GmbH & Co KG

Selva Therapeutics Inc

Soligenix Inc

TFF Pharmaceuticals Inc

Tiba Biotech LLC

Tonix Pharmaceuticals Holding Corp

Uvax Bio LLC

Vaccibody AS

Vaxeal Holding SA

Vir Biotechnology Inc

XBiotech Inc

Xenothera SAS

Yaso Therapeutics Inc

Yisheng Biopharma Co Ltd

Zalgen Labs LLC

Table of Contents

Table of Contents

Introduction

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Overview

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Therapeutics Development

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Therapeutics Assessment

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Companies Involved in Therapeutics Development

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Drug Profiles

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Discontinued Products

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Number of Products under Development by Companies, 2021 (Contd..2)

Number of Products under Development by Companies, 2021 (Contd..3)

Number of Products under Development by Universities/Institutes, 2021

Number of Products under Development by Universities/Institutes, 2021 (Contd..1)

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Products under Development by Companies, 2021 (Contd..3)

Products under Development by Companies, 2021 (Contd..4)

Products under Development by Companies, 2021 (Contd..5)

Products under Development by Universities/Institutes, 2021

Products under Development by Universities/Institutes, 2021 (Contd..1)

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Abivax SA, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by AIkido Pharma Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Akshaya Bio Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by AlphaVax Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by AnGes Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by ANP Technologies Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by AntoXa Corp, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Arisan Therapeutics Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Auro Vaccines LLC, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Avipero Ltd, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Beijing Combio Pharmaceuticals Ltd, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Beijing Mabworks Biotech Co Ltd, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Bharat Biotech Ltd, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by BioComo Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by BioCryst Pharmaceuticals Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by BioFactura Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Biotron Ltd, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Celdara Medical LLC, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Chicago Biosolutions Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Cocrystal Pharma Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Collaborations Pharmaceuticals Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Eisai Co Ltd, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Emergent BioSolutions Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Emergex Vaccines Holding Ltd, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Etubics Corp, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Fab’entech SA, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Fibroplate Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Flow Pharma Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Fox Chase Chemical Diversity Center Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Galactica Biotech Ltd, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Gamaleya Federal Research Center of Epidemiology and Microbiology, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by GeoVax Labs Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Gilead Sciences Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Global BioLife Inc Ltd, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Greffex Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by H&P Labs Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by IDBiologics Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Inovio Pharmaceuticals Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Integral Molecular Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Integrated BioTherapeutics Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by IntelliStem Technologies Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Johnson & Johnson, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Mapp Biopharmaceutical Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Merck & Co Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Microbiotix Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Micropharm Ltd, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Novavax Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Oita University Institute of Advanced Medicine Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by OncXerna Therapeutics Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Orgenesis Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Ostrich Pharma USA Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Palisades Therapeutics, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by PanThera Biopharma LLC, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Phelix Therapeutics LLC, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Phoenix Biotechnology Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Public Health Vaccines LLC, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Regeneron Pharmaceuticals Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Riboscience LLC, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Rodos BioTarget GmbH, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by SAB Biotherapeutics Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Secarna Pharmaceuticals GmbH & Co KG, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Selva Therapeutics Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Soligenix Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by TFF Pharmaceuticals Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Tiba Biotech LLC, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Tonix Pharmaceuticals Holding Corp, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Uvax Bio LLC, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Vaccibody AS, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Vaxeal Holding SA, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Vir Biotechnology Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by XBiotech Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Xenothera SAS, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Yaso Therapeutics Inc, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Yisheng Biopharma Co Ltd, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Zalgen Labs LLC, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Dormant Projects, 2021

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Dormant Projects, 2021 (Contd..1)

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Dormant Projects, 2021 (Contd..2)

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Dormant Projects, 2021 (Contd..3)

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Dormant Projects, 2021 (Contd..4)

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports